Related Experiment Videos
Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR
R A Willemsen1, M E Weijtens, C Ronteltap
1Department of Clinical and Tumor Immunology, Academic Hospital Rotterdam/Daniel den Hoed Cancer Center, The Netherlands.
Gene Therapy
|September 12, 2000
Summary
Genetically engineered T lymphocytes with chimeric T cell receptors (TCR) specifically target MAGE-A1POS/HLA-A1POS cells. These engineered cells demonstrate antitumor reactivity and lymphokine production, showing promise for disease-specific therapies.
Area of Science:
- Immunology
- Molecular Biology
- Cancer Therapy
Background:
- T lymphocytes are crucial for adaptive immunity.
- Chimeric T cell receptors (TCRs) can redirect T cell specificity.
- Melanoma-specific cytotoxic T lymphocyte (CTL) clone 82/30 provides a basis for TCR engineering.
Purpose of the Study:
- To genetically engineer primary human T lymphocytes with chimeric TCRs.
- To assess the specificity and functionality of engineered T cells against MAGE-A1POS/HLA-A1POS cells.
- To evaluate the therapeutic potential of these genetically modified T cells.
Main Methods:
- Constructed single-chain (sc-) and two-chain (tc-) TCR genes from CTL clone 82/30.
- Linked TCR genes to the CD3-zeta signaling element.
- Used retroviral vectors to transduce human peripheral blood lymphocytes.
- Assessed recognition of MAGE-A1POS/HLA-A1POS cells and peptide/MHC complexes.
- Measured antitumor reactivity and lymphokine production.
Main Results:
- Transduced T lymphocytes specifically recognized and responded to MAGE-A1POS/HLA-A1POS cells.
- Engineered cells exhibited specific antitumor reactivity.
- Specific lymphokine production was observed in transduced T lymphocytes.
- Chimeric TCRs were designed to prevent pairing with endogenous TCRs, ensuring predictable specificities.
Conclusions:
- Genetically engineered primary human T lymphocytes expressing chimeric sc- or tc-TCRs are effective against target cells.
- These engineered T cells demonstrate specific antitumor activity and cytokine production.
- Chimeric TCR-engineered T cells hold significant promise for developing novel disease-specific immunotherapies.